AET2023: Discovery of a fully human TCR-mimic antibody developed to target NY-ESO-1/HLA-A02

AET2023: Discovery of a fully human TCR-mimic antibody developed to target NY-ESO-1/HLA-A02

Summary 

Biocytogen’s TCRm antibody discovery platform combines unique immune technology with a multiplex screening method to obtain a high-affinity NY-ESO-1/HLA-A02 antibody, which can bind and specifically kill HLA-A02-positive cell lines presenting NY-ESO-1. This TCRm platform overcomes the limitation of targeting extracellular antigens and displays a wider range of applications.

Share:

    Please fill out the form below to request a download of this poster

    WordPress Double Opt-in by Forge12